Abstract:Background Diabetic cardiovascular complication is a major cause of mortality in type 2 diabetic patients. Hyperglycemia markedly increases the risk of cardiovascular disease. Endothelial dysfunction is common in type 2 diabetes mellitus (DM) and is an early indicator of diabetic vascular disease. Therefore, it is necessary to identify the effect of different hypoglycemic agents on vascular endothelium. The aim of the study was to examine and compare the effects of metformin and gliquidone on atherosclerotic lesions in streptozotocin-induced diabetic rats. Methods Forty male Sprague-Dawley rats (age, 8 weeks; weight, 180–200 g) were included in this study and fed with a normal chow diet for 1 week. Rats (n=10) served as the normal control group (NC group) were fed with a normal chow for another 2 weeks and received an injection of saline. The rest 30 rats fed with a high-fat diet for 2 weeks and injected streptozotocin were randomly assigned to three groups (n=10 rats per group) as follow: type 2 DM group (DM group), DM + gliquidone group (GLI group) and DM + metformin group (MET group). Five weeks later, all rats were fasted overnight and taken tail blood samples for biochemical determinations. Then rats in the NC and DM groups were administrated with normal saline, while rats in the MET and GLI groups were administrated with metformin (100 mg/kg) or gliquidone (10 mg/kg), respectively. All medicines were given via intragastric administration for 8 weeks. After 16 weeks, plasma triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) were measured. The aortic arch was isolated from diabetic rats and was assessed by pathological sectioning using H&E staining. Results Metformin treatment prevented weight gain ((315.80±52.16) g vs. (318.70±68.48) g, P=0.773), improved plasma TG, HDL-C and LDL-C levels (P=0.006, 0.003, 0.001, respectively, all P <0.05). However, gliquidone showed no significant effects on plasma TG and TC levels (P=0.819, 0.053, respectively). LDL-C and HDL-C in the GLI group changed ((0.46±0.10) mmol/L vs. (0.36±0.14) mmol/L, P=0.007; (0.99±0.27) mmol/L vs. (1.11±0.18) mmol/L, P=0.049). Both metformin and gliquidone treatment lowered blood glucose levels (P=0.001, 0.004, respectively, P <0.05). Under light microscopy, no changes were observed in the aortic wall structure of each layer; the intima was smooth and the membrane elastic fibers were normal in the NC group. In the DM group, the aortic wall structure was unclear, the intima was thickened with irregular intima, and membrane elastic fibers collapsed. The aortic intima in the MET and GLI groups was smoother compared with the DM group, but the endothelial structure of the MET group was closer to that of the NC group. Conclusions Both metformin and gliquidone have anti-atherosclerotic effects. But the endothelial structure of the MET group was closer to that of the NC group. Metformin and gliquidone therapy can reduce serum level of LDL-C and increase level of HDL-C, whereas gliquidone therapy did not lose weight and decrease serum level of TG. These data may have important implications for the treatment of patients with type 2 DM.

Anti-diabetic Effect of a Monoamine Oxidase Inhibitor (tranylcypromine) in Rats with Poorly-Controlled Blood Glucose Levels: A Potential and Novel Therapeutic Option for Diabetes

Gliquidone Versus Metformin: Differential Effects on Aorta in Streptozotocin Induced Diabetic Rats

Comparative Efficacy and Safety of Glucose-Lowering Drugs as Monotherapy for Type 2 Diabetes: A Systematic Review and Indirect Treatment Comparison

Choice of Glucose-Lowering Drugs As Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis

PP93 Efficacy of Pharmacological Treatments for Type 2 Diabetes in China

PDG8 EFFICACY OF PHARMACOLOGICAL MONOTHERAPIES FOR TYPE 2 DIABETES IN CHINA

New Insights on the potential therapeutic effects of glibenclamide and Obeticholic acid against Alloxan-Induced diabetes mellitus in rat model

Efficacy of Pharmacological Monotherapies for Type 2 Diabetes in China: A Systematic Review and Meta-Analysis

Evaluating the effectiveness of a novel somatostatin receptor 2 antagonist, ZT-01, for hypoglycemia prevention in a rodent model of type 2 diabetes

Hepatoprotective potential of alpha-lipoic acid against gliclazide-induced liver injury in high-glucose-exposed human liver cells and experimental type 2 diabetic rats

First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis

Comparative Effects of Ethanolic Leaf Extracts of Gongronema latifolium Benth and Bryophyllum pinnatum (Lam.) Oken in The Management of Diabetes Mellitus in Albino Rats

Current treatments and strategies for type 2 diabetes: Can we do better with GLP-1 receptor agonists?

Antidiabetic Potential of Sinigrin Against Streptozotocin-Induced Diabetes via Modulating Inflammation and Oxidative Stress

Therapeutical Potential of T3 as Adjuvant Therapy in Male Alloxan-induced Diabetic Rats

Combined Administration of Metformin and Propionate Reduces the Degree of Oxidative/Nitrosative Damage of Hypothalamic Neurons in Rat Model of Type 2 Diabetes Mellitus

Anti-diabetic effect of cotreatment with resveratrol and pioglitazone in diabetic rats.

Shr3824, A Novel Selective Inhibitor of Renal Sodium Glucose Cotransporter 2, Exhibits Antidiabetic Efficacy in Rodent Models

#4581 EVALUATION OF THE BENEFICIAL EFFECTS OF SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONIST ON TOP OF RAS BLOCKADE IN EXPERIMENTAL DIABETIC NEPHROPATHY

Effect of Shuangyi Jiangtang Preseription on Metabolism of Blood Glucose and Blood Lipids in Type 2 Diabetic Rats

Glucose-lowering effect of dioxopiperazinecarbonylphenylsulfonylcyclohexyl urea